Shattuck Labs Inc (STTK) Stock Price, Quote & News

Company Profile

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also...

Industry: Biotechnology

Sector: Healthcare

Phone: 512 900 4690

Website: www.shattucklabs.com

Address:

500 West 5th Street, Suite 1200, Austin, United States

StockScanners Jun. 27 at 6:04 PM

$STTK keep watch if this holds above 6.29

0 · Reply

NyseDayTrader Jun. 26 at 8:59 PM

$STTK 12.2 million today!

0 · Reply

NyseDayTrader Jun. 26 at 3:28 PM

$STTK is starting to look real interesting. Here's what I'm seeing... 💰 Around **$220M** available to fund operations. 👊 Insiders didn't just talk—they bought with their own money. 📈 June wasn't normal. A **5.5M+ share trading day** followed by trading volume that appeared to run at roughly **double the stock's recent average**. That's not an accident. Somebody was paying attention. Now the company has the cash to execute, insiders have skin in the game, and the tape is finally waking up. I'd rather be early than chase it after everyone suddenly decides they "found" it. My money is already where my conviction is. $STTK 🚀

0 · Reply

ozzarch Jun. 25 at 6:37 PM

$STTK okay lets don't wreck a great week

0 · Reply

NyseDayTrader Jun. 25 at 6:11 PM

$STTK added more here

0 · Reply

StockScanners Jun. 25 at 1:02 AM

$STTK keep watch if this holds above 6.11

0 · Reply

YushimiCloud Jun. 24 at 6:37 PM

$STTK getting volume now lets get it

0 · Reply

ozzarch Jun. 24 at 5:54 PM

$STTK sleeping dragon has awoke

0 · Reply

NyseDayTrader Jun. 24 at 4:33 PM

$STTK

0 · Reply

NyseDayTrader Jun. 17 at 4:27 PM

$STTK added more at $ 4.60

0 · Reply

Shattuck Labs 10.9M share Spot Secondary priced at $4.00

Jun 10, 2026, 12:21 AM EDT - 19 days ago

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

2026-06-09T20:30:52.000Z - 19 days ago

Shattuck Labs TBA Spot Secondary; price range $4.00-$4.25

2026-06-09T20:20:20.000Z - 19 days ago

Shattuck Labs announces common stock offering, no amount given

Jun 9, 2026, 4:18 PM EDT - 19 days ago

Shattuck Labs, Inc. Announces Proposed Public Offering

Jun 9, 2026, 8:00 AM EDT - 20 days ago

Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update

2026-06-09T09:55:40.000Z - 20 days ago

Shattuck Labs price target raised to $18 from $7 at Citi

2026-06-08T15:20:25.000Z - 20 days ago

Shattuck Labs price target raised to $17 from $14 at Needham

Jun 8, 2026, 8:00 AM EDT - 21 days ago

Shattuck Labs Transcript: Study result

Jun 8, 2026, 8:00 AM EDT - 21 days ago

Shattuck Labs Press release: Study result

Jun 8, 2026, 8:00 AM EDT - 21 days ago

Shattuck Labs Slides: Study result

2026-06-08T10:10:51.000Z - 21 days ago

Shattuck Labs announces Phase 1 results for SL-325

Jun 8, 2026, 6:00 AM EDT - 21 days ago

Shattuck Labs Announces Phase 1 Results for SL-325

Jun 5, 2026, 4:05 PM EDT - 23 days ago

Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

2026-06-05T09:55:07.000Z - 24 days ago

Citi opens ‘upside 30-day catalyst watch’ on Shattuck into data

2026-06-05T01:05:18.000Z - 24 days ago

Shattuck Labs upgraded to Buy from Neutral at Citi

2026-05-08T13:46:57.000Z - 7 weeks ago

Shattuck Labs price target raised to $11 from $8 at Wedbush

2026-05-07T16:39:16.000Z - 7 weeks ago

Shattuck Labs reports Q1 EPS (13c), consensus (13c)

2026-05-07T16:38:04.000Z - 7 weeks ago

Shattuck Labs sees cash and cash equivalents sufficient into 2029

May 7, 2026, 7:00 AM EDT - 7 weeks ago

Shattuck Labs Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 7 weeks ago

Shattuck Labs Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 7 weeks ago

Shattuck Labs Slides: Corporate presentation

May 7, 2026, 6:15 AM EDT - 7 weeks ago

Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights

2026-04-27T11:35:53.000Z - 2 months ago

Shattuck Labs initiated with an Overweight at Cantor Fitzgerald

2026-04-20T10:10:31.000Z - 2 months ago

Shattuck Labs price target raised to $18 from $6 at H.C. Wainwright

Apr 8, 2026, 8:00 AM EDT - 2 months ago

Shattuck Labs Proxy statement: Proxy filing

Apr 8, 2026, 8:00 AM EDT - 2 months ago

Shattuck Labs Proxy statement: Proxy filing

2026-04-02T14:51:15.000Z - 3 months ago

Shattuck Labs management to meet with Piper Sandler

2026-03-13T10:50:49.000Z - 3 months ago

Citi ups Shattuck Labs target, opens ‘upside 90-day catalyst watch’

2026-03-06T12:46:35.000Z - 4 months ago

Shattuck Labs price target raised to $8 from $4 at Wedbush

2026-03-06T10:46:48.000Z - 4 months ago

Shattuck Labs transferred with Buy rating at Needham

Mar 5, 2026, 7:00 AM EST - 4 months ago

Shattuck Labs Slides: Corporate presentation

Mar 5, 2026, 6:30 AM EST - 4 months ago

Shattuck Labs Annual report: Q4 2025

Mar 5, 2026, 6:30 AM EST - 4 months ago

Shattuck Labs Earnings release: Q4 2025

2026-03-05T11:22:07.000Z - 4 months ago

Shattuck Labs reports Q4 EPS (12c), consensus (13c)

2026-03-05T11:21:30.000Z - 4 months ago

Shattuck Labs expects available cash to fund operations into 2029

Mar 5, 2026, 6:15 AM EST - 4 months ago

Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights

Mar 2, 2026, 9:10 AM EST - 4 months ago

Shattuck Labs Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 8:00 AM EST - 4 months ago

Shattuck Labs Announces Participation in Upcoming March Investor Conferences

Feb 6, 2026, 8:30 AM EST - 5 months ago

Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium

Jan 13, 2026, 7:00 AM EST - 5 months ago

Shattuck Labs Registration statement: Registration Filing

Dec 15, 2025, 4:15 PM EST - 6 months ago

Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 4, 2025, 8:20 AM EST - 7 months ago

Shattuck Labs Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 10:10 AM EST - 7 months ago

Shattuck Labs Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 20, 2025, 8:00 AM EST - 7 months ago

Shattuck Labs to Participate in Upcoming December Investor Conferences

Nov 6, 2025, 4:30 PM EST - 8 months ago

Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:00 AM EST - 8 months ago

Shattuck Labs Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 8 months ago

Shattuck Labs Quarterly report: Q3 2025

Nov 6, 2025, 2:00 AM EST - 8 months ago

Shattuck Labs Slides: Corporate Presentation

Oct 8, 2025, 10:00 AM EDT - 9 months ago

Shattuck Labs Transcript: The United European Gastroenterology (UEG) Congress UEG Week 2025

Oct 2, 2025, 7:51 AM EDT - 9 months ago

Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel

Sep 18, 2025, 8:00 AM EDT - 10 months ago

Shattuck Labs Registration statement: Registration Filing

Aug 26, 2025, 6:30 AM EDT - 10 months ago

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

Aug 21, 2025, 10:17 AM EDT - 11 months ago

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

Aug 14, 2025, 4:00 PM EDT - 11 months ago

Shattuck Labs Earnings release: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 11 months ago

Shattuck Labs Quarterly report: Q2 2025

Aug 14, 2025, 6:30 AM EDT - 11 months ago

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 5, 2025, 6:30 AM EDT - 11 months ago

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

Jul 2, 2025, 7:00 AM EDT - 1 year ago

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

May 21, 2025, 8:00 AM EDT - 1 year ago

Shattuck Labs Proxy statement: Proxy Filing

May 21, 2025, 8:00 AM EDT - 1 year ago

Shattuck Labs Proxy statement: Proxy Filing

May 1, 2025, 4:20 PM EDT - 1 year ago

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025, 7:00 AM EDT - 1 year ago

Shattuck Labs Slides: Corporate Presentation

Apr 30, 2025, 6:00 PM EDT - 1 year ago

Shattuck Labs Quarterly report: Q1 2025

Apr 30, 2025, 6:00 PM EDT - 1 year ago

Shattuck Labs Earnings release: Q1 2025

Apr 9, 2025, 3:00 PM EDT - 1 year ago

Shattuck Labs Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 5:00 PM EDT - 1 year ago

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Mar 26, 2025, 7:00 PM EDT - 1 year ago

Shattuck Labs Earnings release: Q4 2024

Mar 26, 2025, 7:00 PM EDT - 1 year ago

Shattuck Labs Annual report: Q4 2024

Feb 20, 2025, 9:00 AM EST - 1 year ago

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Feb 13, 2025, 4:30 PM EST - 1 year ago

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Feb 4, 2025, 7:00 AM EST - 1 year ago

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress

Jan 16, 2025, 10:30 AM EST - 1 year ago

Shattuck Labs Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 6, 2025, 4:59 PM EST - 1 year ago

Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 7:00 AM EST - 1 year ago

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025

Dec 4, 2024, 8:45 AM EST - 1 year ago

Shattuck Labs Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 12:30 PM EST - 1 year ago

Shattuck Labs Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 14, 2024, 7:00 AM EST - 1 year ago

Shattuck Labs Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

Shattuck Labs Earnings release: Q3 2024

Oct 1, 2024, 12:23 PM EDT - 1 year ago

Shattuck Labs' stock craters as biotech scraps main product candidate after failed trial

Oct 1, 2024, 8:00 AM EDT - 1 year ago

Shattuck Labs Transcript: Study Update

Oct 1, 2024, 8:00 AM EDT - 1 year ago

Shattuck Labs Press release: Study Update

Oct 1, 2024, 8:00 AM EDT - 1 year ago

Shattuck Labs Slides: Study Update

Oct 1, 2024, 7:00 AM EDT - 1 year ago

Shattuck Labs Slides: Corporate Presentation

Oct 1, 2024, 6:30 AM EDT - 1 year ago

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

Aug 1, 2024, 9:30 AM EDT - 2 years ago

Shattuck Labs Quarterly report: Q2 2024

Aug 1, 2024, 9:30 AM EDT - 2 years ago

Shattuck Labs Earnings release: Q2 2024

Aug 1, 2024, 7:00 AM EDT - 2 years ago

Shattuck Labs Slides: Corporate Presentation

Jul 30, 2024, 5:00 PM EDT - 2 years ago

Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference

Jul 1, 2024, 6:00 AM EDT - 2 years ago

Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes

Jun 14, 2024, 12:00 PM EDT - 2 years ago

Shattuck Labs Transcript: Study Update

Jun 14, 2024, 12:00 PM EDT - 2 years ago

Shattuck Labs Press release: Study Update

Jun 14, 2024, 12:00 PM EDT - 2 years ago

Shattuck Labs Slides: Study Update

Jun 14, 2024, 6:00 AM EDT - 2 years ago

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leuk

StockScanners Jun. 27 at 6:04 PM

$STTK keep watch if this holds above 6.29

0 · Reply

NyseDayTrader Jun. 26 at 8:59 PM

$STTK 12.2 million today!

0 · Reply

NyseDayTrader Jun. 26 at 3:28 PM

0 · Reply

ozzarch Jun. 25 at 6:37 PM

$STTK okay lets don't wreck a great week

0 · Reply

NyseDayTrader Jun. 25 at 6:11 PM

$STTK added more here

0 · Reply

StockScanners Jun. 25 at 1:02 AM

$STTK keep watch if this holds above 6.11

0 · Reply

YushimiCloud Jun. 24 at 6:37 PM

$STTK getting volume now lets get it

0 · Reply

ozzarch Jun. 24 at 5:54 PM

$STTK sleeping dragon has awoke

0 · Reply

NyseDayTrader Jun. 24 at 4:33 PM

$STTK

0 · Reply

NyseDayTrader Jun. 17 at 4:27 PM

$STTK added more at $ 4.60

0 · Reply

topstockalerts Jun. 13 at 12:34 AM

$STTK that was a very convincing response.

0 · Reply

NyseDayTrader Jun. 12 at 11:33 PM

$STTK 😉

0 · Reply

prismmarketview Jun. 12 at 4:01 PM

PRISM Mid-Day Movers: New Energy and Fintech Are Today’s Leaders. LanzaTech Global, Inc. (NASDAQ: $LNZA ) is trading solidly higher today, climbing about 16% to 7.2801 from a prior close of 6.25. SHF Holdings, Inc. (NASDAQ: $SHFS ), which operates as Safe Harbor Financial, is catching a bid today, with the stock up about 13% intraday as buyers step back into this beaten‑down cannabis‑banking platform after a string of heavy selling. Other Notable Movers: TherapeuticsMD, Inc. ( $TXMD ) up 12% Shattuck Labs. ( $STTK) up 12% Sleep Number Corp. ( $SNBR) down -42% https://prismmarketview.com/prism-mid-day-movers-new-energy-and-fintech-are-todays-leaders/

0 · Reply

NyseDayTrader Jun. 12 at 12:04 PM

$STTK

0 · Reply

FilingTracker Jun. 11 at 9:01 PM

$STTK Insider purchase: https://filingtracker.ai/filing/1680367/0001193125-26-267836

0 · Reply

OpenOutcrier Jun. 10 at 12:44 PM

$STTK (-6.6% pre) Shattuck Labs prices $75 million public offering at $4 per share https://ooc.bz/l/104732

0 · Reply

briefingcom Jun. 10 at 12:22 PM

$STTK: Shattuck Labs (-4.9%) prices $75 mln public offering consisting of common stock and warrants.

0 · Reply

Merlintrader Jun. 10 at 7:24 AM

$IDYA $IDYA, $STTK, $ELOX: Biotech Funding Window Reopens, But Not All Dilution Looks the Same https://www.merlintrader.com/biotech-funding-window-reopens/

0 · Reply

NyseDayTrader Jun. 9 at 8:28 PM

$STTK what just happened??

1 · Reply

NyseDayTrader Jun. 9 at 6:39 PM

$STTK quietly have been entering back here

0 · Reply

anachartanalyst Jun. 9 at 3:01 PM

$STTK https://anachart.com/wp-content/uploads/2026/06/1781017286_soc-img.jpg

0 · Reply

DARKP00L Jun. 9 at 12:48 PM

$STTK 08:05 on Jun. 09 2026 Shattuck Labs Announces Total Expected Proceeds Of ~$59.4M From Exercised Warrants #tradeideas

0 · Reply

Market Cap	493.83M
Revenue (ttm)	1.00M
Net Income (ttm)	-48.81M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,881.00%
Debt to Equity Ratio	0.00

Volume	12,486,800
Avg Vol	1,029,330
Day's Range	N/A - N/A
Shares Out	76.68M
Stochastic %K	98%
Beta	1.08
Analysts	Strong Sell
Price Target	$14.83